A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.

A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00163111

Enrollment

412

Registered

2005-09-13

Start date

1998-09-30

Completion date

2003-05-31

Last updated

2011-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidiasis

Brief summary

This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients

Interventions

DRUGVFENDÂ® I.V., Oral

DRUGConventional amphotericin B

DRUGDiflucan IV, oral

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with candidemia

Exclusion criteria

* Neutropenia

Design outcomes

Primary

Measure	Time frame
Sustained clinical response for 12 weeks from end of treatment	—

Secondary

Measure	Time frame
Time to negative blood cultures	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026